In summary, the current study revealed that silencing of ACAT1 enhanced the activation and cell proliferation of anti-CD19-CAR T cells, and the capacity of anti-B-cell lymphoma was also improved both in vitro and in vivo. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.